To expand the access and delivery of COVID-19 Vaccines in Africa (ECOVA), theinvestigators will conduct a phase 3, individually randomized, observer-blind, controlled(influenza vaccine) trial to evaluate the safety and efficacy of the BBIBP-CorV vaccineagainst any severe acute respiratory syndrome 2 (SARS-CoV- 2) infection among adults 18years and older. The BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell)manufactured by the Beijing Institute of Biological Products (BIBP), China NationalBiotec Group (CNBG), Sinopharm, Beijing, People's Republic of China and receivedemergency use authorization (EUA) from World Health Organization (WHO).

The aim of this study is to investigate the effectiveness of virtual reality exercises onpain, cardiopulmonary capacity, mood and quality of life in patients with post-COVIDsyndrome.

This is a prospective study in which a process of identifying and improving a reductionof functional capacity in COVID-19 survivors >50 years old.The overall goal of this study to identify the feasibility and value of risk-guidedmedical therapy and exercise intervention in COVID-19 survivors.

Background:Inequalities in COVID-19 infection, hospitalization, and death in under-studied,under-represented, and under-reported groups of people are severe. A growing number ofstudies have assessed the impact of individual risk factors. But few studies haveassessed which factors are the greatest drivers of COVID-19 disparities from a widerperspective.Objective:To understand the long-term impacts of COVID-19 on minority women and their families toassist in developing community-based programs to help in recovery.Eligibility:Healthy people aged 18 and older who reside in North Carolina.Design:Participants will take a 45-minute online survey. The survey will cover theirdemographics, community, health, lifestyle, household, and environment.Participants may choose to have tests. They may visit the Clinical Research Unit. Theymay also have a home visit for these tests. In some cases, they may mail samples to thestudy team in prepaid envelopes.Participants may take an optional 15 minute survey about their reproductive history.Participants may give a blood sample.Participants may give a urine sample. They will fill out a log and return with theirsample.Participants may give saliva samples.Participants may give toenail samples from each toe.Participants may give dust samples. They will be given 8 alcohol swabs. Two will be fortesting. They will be asked to swipe a total of 3 door frames. Each door frame should bein a different room of the house.Participants may be given silicone wristbands to wear for 1 week. This is to measuretheir exposure to air pollutants.Participants may be contacted in the future for follow-up. They may be contacted byphone, email, or letter.

The purpose of this double-blind, randomized, controlled study is to assess safety,reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels,administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age andabove.

The main objectives of ECCO-2 are: 1) Efficacy: to study whether EQUINACEA ARKOPHARMA,hard caplets containing cryogenized root of the plant Echinacea purpurea, show animprovement of the clinical manifestations and disease course in ambulatory patients withcovid-19 with a respiratory presentation and not requiring hospitalization (i.e., mildcovid-19). The drug being evaluated will be added as a supplement of the standardtreatment, with its current recommended dose for treatment of the common cold. 2) Safety:to determine that the incidence of adverse events is not higher than that seen with thestandard treatment applied in each case.

The XPHI-COVID-2 randomized study aims to investigate the moral choices in a context ofscarce resources.The participants are asked to complete the questionnaire of the Oxford UtilitarianismScale and are exposed to medical triage dilemmas.Participants are randomized between a group with reading of ethical guidelines and agroup without reading of ethical guidelines, before they are asked to complete thequestionnaire and being exposed to triage dilemmas.

Repetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment fordepression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn howto optimize the treatment to improve symptoms of depression and OCD. This researchproject will test a new accelerated 5-day accelerated rTMS protocol for treating symptomsof depression and OCD.A second goal of this study is to identify biomarkers of depression and OCD in the brainusing functional magnetic resonance imaging (fMRI). This approach will predict who willbenefit from TMS, determine the optimal treatment target, and improve treatment outcomes.Subjects will receive a clinical assessment of symptoms and an fMRI brain scan before andafter each treatment course to measure the effect of treatment on symptom severity and onfMRI measures of functional connectivity.Participants will be randomized to receive rTMS targeting either the lateral prefrontalcortex (LPFC) or the dorsomedial prefrontal cortex (DMPFC). Participants will complete a5-day course of rTMS delivered hourly for 10 hours per day. Participants who show apartial response to treatment but not a full response will then receive a second 5-daycourse. Treatment non-responders will be crossed over to receive rTMS targeting theopposite brain area.The primary hypothesis is that accelerated rTMS treatment will yield rapid improvement insymptoms for patients with depression and OCD in just 5 days, and that response rates canbe further improved by adding a second 5-day treatment course.

This study aims to examine the association between gut microbiota composition and themagnitude and duration of immune response in subjects who have received differentCOVID-19 vaccines in Hong Kong and to identify the differences compared to those COVID-19recovered subjects.

This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65years who have received three doses of mRNA vaccine will be randomized to vaccinationwith a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine or to vaccination with acontrol (Prevnar-13 vaccine).